What a Florida IV clinic needs to safely offer add-ons and shots — Toradol, Zofran, B12, lipo/MIC, vitamin C, glutathione, NAD+ and more: get each product, dose, and route into the standing orders your medical director signs.
Clinical governance reviewed by Armando A. Falcon, MD (FL ME 84789) · Florida regulatory framework reviewed August 2026.
Usually yes — clinics offer these all the time, both as IV add-ons and as IM/SC “shots” (B12, lipo/MIC, vitamin D, plus meds like Toradol and Zofran). The one rule that keeps you safe and compliant: each product and route has to be written into the standing orders and protocols your medical director signs. That protocol names the product, the dose, the route, who it’s appropriate for, and when to hold — so your team is following a doctor’s orders, not guessing at the chair. Get that in place and an add-on menu is straightforward.
Clinics lump very different products under “IV add-on” — prescription drugs (ketorolac, ondansetron, dexamethasone, famotidine), prescription injectable vitamins (B12, B-complex, vitamin C), and compounded sterile preparations (glutathione, NAD+). They should not share one generic protocol: some are prescription medications, some have route-specific labeling, some are compounded, and some carry important contraindications or monitoring needs. For each, answer: what exactly is the product, is it a prescription drug, what route is it labeled/prepared for, who may prescribe and who may administer, is it commercial or compounded, and what claims can responsibly be made.
Toradol (a powerful anti-inflammatory for pain) is popular and fine to offer — but it’s a real medication, not a vitamin. It’s not right for everyone (people with kidney problems, ulcers or bleeding history, blood thinners, or who are pregnant), so it can’t just sit on the menu as “Pain relief +$25.” Your MD-signed protocol should spell out who it’s okay for, who screens them, the dose, and when to say no. Handled that way, it’s a solid add-on.
Zofran (anti-nausea) is a common add-on and a prescription medicine. The simple version: a nurse shouldn’t decide on her own to add it because a client “feels queasy.” Instead, your protocol pre-authorizes it — who qualifies, the dose, and when to give it — so the nurse is following the doctor’s standing order, not prescribing. If the nausea looks like something more serious, the protocol says escalate. That’s the whole structure.
These are bread-and-butter offerings and there’s nothing scary about them. Two easy things to get right: B12 is a prescription vitamin that’s normally given as an IM shot, not dropped into an IV bag — so the protocol should name the product and the route. And IV vitamin C comes in a few different strengths, so the protocol names the product and dose. That’s really it — list each vitamin, its dose, and its route in the standing orders your MD signs, and your team gives the right thing the right way every time.
A lot of your menu can be given as a quick intramuscular or under-the-skin shot instead of a drip — B12, lipo/MIC (“skinny”) shots, vitamin D, and even meds like Toradol or Zofran. Same simple rule: the shot, its dose, and its route go in the standing orders your medical director signs. The one thing to nail is the route — B12, for example, is normally an IM shot, so the protocol should say “IM,” not “add to the IV.” Shots are quick and low-drama; they just belong on the signed protocol like everything else.
These sell well and are fine to offer — the thing that actually matters is where you buy them. They’re compounded products, and the problems that have made the news came from cheap or non-sterile-grade sources, not from the ingredients themselves. So buy from a reputable, licensed compounding pharmacy, keep the lot and expiration on file, and put the product, dose, and route in your MD-signed protocol like anything else. NAD+ is worth its own protocol line because it’s infused slowly — people feel it if it runs too fast. And keep the marketing honest: sell it as wellness, not as a cure for aging, addiction, or disease.
Florida nursing law treats medication administration as nursing when prescribed/authorized by an appropriate practitioner. Correct structure: authorized clinician evaluates and orders → RN confirms eligibility under the order → RN administers and monitors → RN stops/escalates per explicit criteria. Poor structure: patient checks a box on a menu → RN decides it seems fine → RN adds the drug. Each add-on also needs its own “who can get it / when to hold” list — the right health-history checks for that specific product (allergies, kidney or heart issues, pregnancy, blood thinners, dose limits, how often it can be repeated) — not one blanket “anyone without allergies” line.
Approval of a hydration program is not automatic approval of every future ingredient. A good sequence: clinic proposes the add-on → product identified (manufacturer/pharmacy, concentration, route) → labeling/evidence reviewed → eligibility and contraindications defined → prescribing/order workflow set → RN execution rules written → monitoring and emergency response defined → sourcing verified → chart fields built → marketing reviewed → medical director approves → staff trained. Update the emergency plan whenever the menu changes — NSAIDs, antiemetics, steroids, high-dose nutrients, and compounded antioxidants raise the risk profile beyond isotonic hydration.
“It’s just an add-on” (an injectable Rx is still a medical treatment); “the RN can decide” (administration ≠ prescribing); “it’s a vitamin, so route doesn’t matter” (product labeling and route are specific); “the pharmacy sells it, so we can use it” (availability doesn’t validate your workflow); “all ingredients can go in one bag” (compatibility/stability/route matter); “the MD already approved IV therapy” (new drugs need new approval); and “NAD+ is just another wellness vitamin” (separate sourcing, safety, evidence, and quality review).
Every new IV add-on changes the clinic’s clinical risk profile. Before it reaches the menu, verify the exact product, prescribing authority, patient-selection criteria, route, source, preparation method, nursing workflow, monitoring, emergency response, and documentation. Confirm product labeling via DailyMed and current FDA compounding guidance, and confirm your workflow with counsel and your supervising physician.
Disclaimer — B2B clinical-governance & compliance education only. This content is general business, clinical-governance, and compliance information for healthcare practices. It does not create a physician-patient relationship, provide patient-specific medical advice or prescribing authority, or constitute legal advice. Requirements vary by ownership, services offered, provider credentials, payer model, facility type, and whether a practice is licensed or exempt — clinics remain responsible for independently verifying the current laws, rules, and professional requirements that apply to their structure and services before implementation.
Florida Statutes §464.003 — Nurse Practice Act definitions (professional & practical nursing)
Florida Statutes Chapter 465 — Pharmacy Act (compounding & dispensing)
Florida Board of Pharmacy
DailyMed (NIH) — FDA product labeling (verify route, warnings, contraindications)
FDA — concerns with using dietary-ingredient glutathione to compound sterile injectables
FDA — reminder to use ingredients suitable for sterile compounding (NAD+ adverse events)
IV Therapy — medical director services
All Florida medical-director resources
Medical director services across Central and South Florida — 20 metros in three corridors: Gulf Coast (Naples, Fort Myers, Cape Coral, Port Charlotte, Sarasota, Bradenton, Tampa, St. Petersburg, Clearwater, Tarpon Springs), Southeast (Palm Beach, Boca Raton, Fort Lauderdale, Hollywood, Miami, Miami Beach, Kendall), and the I-4 corridor (Lakeland, Orlando, Daytona Beach).
Under the medical direction of Armando A. Falcon, MD (FL ME 84789). Serving Central and South Florida — Gulf Coast, Southeast, and the I-4 corridor. Call or WhatsApp +1 (305) 877-7507.